Update! Now will be looking for data.
$Ocugen (OCGN.US)$ Ocugen Announces Completion of Dosing in Subjects With Stargardt Disease in High Dose Cohort of Phase 1/2 Gardian Clinical Trial of Ocu410St—a Modifier Gene Therapy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
